CORVUS PHARMACEUTICALS, INC. AMENDMENT NO. 1 TO OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • May 1st, 2024 • Corvus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Reference is made to the Open Market Sale AgreementSM, dated March 28, 2023 (the “Agreement”), by and between Corvus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Jefferies LLC (“Jefferies”). The Company and Jefferies (collectively, the “Parties”) wish to amend the Agreement, pursuant to Section 8(h) of the Agreement, to reduce the aggregate offering price under the Agreement (this “Amendment”). The Parties therefore hereby agree as follows:
